Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis.
J Pediatric Infect Dis Soc
; 10(2): 201-204, 2021 Mar 26.
Article
em En
| MEDLINE
| ID: mdl-32448902
ABSTRACT
Pharmacological interactions limit treatment options for children living with human immunodeficiency virus (HIV) and tuberculosis (TB). We found that 12 mg/kg twice daily raltegravir chewable tablets (administered after crushing) safely achieved pharmacokinetic targets in children living with HIV aged 4 weeks to <2 years receiving concurrent rifampin to treat TB. CLINICAL TRIALS REGISTRATION NCT01751568.
Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Tuberculose
/
Infecções por HIV
/
Fármacos Anti-HIV
Limite:
Child
/
Humans
Idioma:
En
Revista:
J Pediatric Infect Dis Soc
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Estados Unidos